Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Focused radiation as sole therapy
What ifWhat if focused external beam radiation provides the entire antitumor treatment?
Claim language“a first active agent combined with at least a second active agent”
A treatment planning system uses magnetic resonance and computed tomography images to define the target and adjacent sensitive structures. A linear accelerator delivers shaped photon beams that damage DNA in the target.
1.1Mechanical tumor removal
What ifWhat if image-guided surgical resection provides the entire antitumor treatment?
Claim language“a first active agent combined with at least a second active agent”
Preoperative magnetic resonance images guide access to a resectable tumor. An ultrasonic aspirator fragments and removes tumor tissue, and intraoperative mapping identifies functional boundaries that limit resection.
1.2Additive tumor growth inhibition
What ifWhat if the two agents produce an additive reduction in tumor growth?
Claim language“a synergistic effect”
Single-agent groups establish the fractional growth inhibition for each agent at the doses used in the combination group. The additive reference equals the sum of those fractions minus their product, and the measured combination response matches that reference within a prespecified margin.
1.3Platinum based DNA damage
What ifWhat if carboplatin serves as the first active agent?
Claim language“first active agent is lomustine”
Carboplatin forms platinum adducts that distort DNA and impede replication. The most common lesions are crosslinks between neighboring bases on the same strand.
1.3Blockade of vascular signaling
What ifWhat if the second agent binds vascular endothelial growth factor?
Claim language“inhibitor of the Fanconi anemia pathway”
A monoclonal antibody binds soluble vascular endothelial growth factor and reduces its activation of receptors on endothelial cells. This reduces vascular permeability and limits signaling that supports new blood vessel formation.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Component substitution
Transcriptional repression of FANCD2 in cells
Glioma cells express catalytically inactive Cas9 fused to a transcriptional repression domain, and a guide RNA directs the fusion to the FANCD2 promoter. Reduced FANCD2 expression supplies the pathway inhibition in cultures exposed to a lomustine concentration series. The assay compares colony formation across targeted and nontargeting guide conditions with matched drug-free controls.
Specific version of a part
Separate oral dosage forms
One capsule contains the first agent, and a separate dosage form contains the second agent. A dosing calendar specifies the administration time for each agent within the same treatment cycle.
Synergy measured by tumor growth
A glioma animal study uses vehicle, two single-agent groups, and a combination group at matched agent doses. Serial magnetic resonance imaging measures tumor growth, and the analysis identifies synergy when combination inhibition exceeds the prespecified additive reference by more than the estimated measurement uncertainty.
Suppression of FANCD2 expression
In an experimental glioma model, lomustine produces DNA crosslinks and a short interfering RNA reduces FANCD2 expression. The RNA guides degradation of FANCD2 messenger RNA and reduces the amount of FANCD2 available for crosslink repair.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
1.1the administration to said subject of a first active agent combined with at least a second active agent
The invention provides a method for inhibiting tumor volume comprising administering an effective amount of a lymphotoxin-beta receptor (LT-β-R) agonist and an effective amount of at least one chemotherapeutic agent, wherein the administration of the LT-β-R agonist and the chemotherapeutic agent results in supra-additive inhibition of the tumor.
A · US 2006/0134102 A1 · ¶ 5
The advantages of this invention are: 1) It can avoid the side effects of oral small molecule multi-kinase inhibitors by using a local delivery route; 2) The biologic drug not only has its own efficacy against the neovascular disease but also acts as a carrier of small molecule agents to enhance its original effects and to modulate additional targets; 3) Cleavable linker can be designed to be hydrolyzed near the target tissue such as in vitreous humor, aqueous humor, sub-teno
B · US 10,835,617 B2 · ¶ 35
1.2wherein the combination of said first and said at least second active agent, when administered to a subject, results in a synergistic effect
In one embodiment, a method for inhibiting tumor volume comprises administering an effective amount of a lymphotoxin-beta receptor (LT-β-R) agonist and an effective amount of a chemotherapeutic agent, which is not a lymphotoxin receptor agonist, wherein the administration of the LT-β-R agonist and the chemotherapeutic agent results in supra-additive inhibition of the tumor.
A · US 2006/0134102 A1 · ¶ 15
It utilizes the synergism between an antibody and a small molecule agent to achieve better effects than either single component alone.
B · US 10,835,617 B2 · ¶ 31
1.3wherein said first active agent is lomustine and said at least second active agent is an ‘inhibitor of the Fanconi anemia pathway’.
An empty cell means only that no passage was reproduced there.
Statements in these documents
Thus, curbing the growth of neoplastic cells and treating various cancers is and will likely continue to be a major health need.
A · US 2006/0134102 A1 · ¶ 3
The combination of the agonist and agent achieves inhibition of a tumor greater than that expected by the simple addition of the effects of the agonist and agent alone.
A · US 2006/0134102 A1 · ¶ 4
For example, targeting additional pathogenesis-related growth factors besides VEGF, longer interval between injections, the desire for neovascular regression and the need to treat ranibizumab-refractory patients are currently unmet.
B · US 10,835,617 B2 · ¶ 3
In one embodiment, the discease is an ocular disease, a dermatological disease, or a joint disease.
B · US 10,835,617 B2 · ¶ 5
Cite aspatent.fyi, US 2026/0355134 A1, claim 1, first published 2026-11-19T08:28:42-05:00, https://patent.fyi/US20260355134/, SHA-256 b7a3b8b3736e0b0d980c9f7d72c276b909fdb493f6ddfad46ebe39b738312a7b